Off-the-Shelf immune cells take on tough lymphoma
NCT ID NCT05653271
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims to see if the treatment is safe and tolerable, and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ACE1831 (a type of immune cell from healthy donors, combined with an antibody to target cancer cells)
What this could lead to
If this works, it could offer a new treatment option for people with B-cell lymphoma who have run out of standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 42 people, so it is mainly checking safety. The therapy may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Orlando
Orlando, Florida, 32804, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Kaohsiung Chang-Gung Memorial Hospital
Kaohsiung City, Kaohsiung, Taiwan
-
Linkou Chang-Gung Memorial Hospital
Taoyuan City, Taiwan
-
Ministry of Health and Welfare Shuang-Ho Hospital
New Taipei City, Taiwan, Taiwan
-
National Cheng Kung University Hospital
Tainan, Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taipei, Taiwan
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
Queen Mary Hospital
Hong Kong, Hong Kong, Hong Kong
-
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan
-
Tamsui MacKay Memorial Hospital
New Taipei City, Taiwan
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States